Janux Therapeutics (JANX) CEO makes bona fide gift of 123,840 shares
Rhea-AI Filing Summary
Janux Therapeutics, Inc. director and President and CEO David Alan Campbell reported a bona fide gift of 123840.0000 shares of Common Stock on July 31, 2026. The transfer was recorded at $0.0000 per share, and he now directly holds 264742.0000 shares following the transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 123,840 shares
Net Sell
1 txn
Insider
Campbell David Alan
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 123,840 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 264,742 shares (Direct)
Key Figures
Shares gifted: 123840.0000 shares
Holdings after transaction: 264742.0000 shares
Gift price per share: $0.0000 per share
3 metrics
Shares gifted
123840.0000 shares
Bona fide gift of Common Stock on July 31, 2026
Holdings after transaction
264742.0000 shares
Directly owned Common Stock following the gift
Gift price per share
$0.0000 per share
Transfer recorded with no per-share consideration
Key Terms
bona fide gift, Rule 10b5-1 trading plan, indirect ownership
3 terms
bona fide gift regulatory
"transaction_code_description: "Bona fide gift""
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Rule 10b5-1 trading plan regulatory
"Footnotes may reference Rule 10b5-1 trading plans"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
indirect ownership financial
"direct_or_indirect uses D/I for Direct/Indirect ownership type"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did JANX report for CEO David Alan Campbell?
Janux Therapeutics (JANX) reported that President and CEO David Alan Campbell made a bona fide gift of 123840.0000 shares of Common Stock on July 31, 2026. The transaction was reported at $0.0000 per share as a non-cash transfer of ownership.
What are David Alan Campbell’s JANX holdings after the reported gift?
After the reported bona fide gift, David Alan Campbell directly holds 264742.0000 shares of Janux Therapeutics (JANX) Common Stock. This post-transaction balance reflects his remaining direct ownership as reported in the insider ownership data.
Was the JANX CEO’s stock gift made under a Rule 10b5-1 trading plan?
The data indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false) for this transaction. That means the reported bona fide gift of 123840.0000 shares was not designated as executed under a pre-arranged 10b5-1 trading plan.
What does transaction code G mean in the JANX Form 4 for the CEO?
In the Janux Therapeutics (JANX) Form 4, transaction code G is described as a “bona fide gift.” This indicates David Alan Campbell’s transfer of 123840.0000 shares was a gift of Common Stock, not a market sale or purchase for cash consideration.
Is the JANX CEO’s gifted stock classified as direct or indirect ownership?
The gifted shares are reported with ownership type direct (code D). After the bona fide gift of 123840.0000 shares, David Alan Campbell’s remaining 264742.0000 shares of Janux Therapeutics Common Stock are also classified as directly owned.